VIB INKS QBASE+ GROUP LICENSING AGREEMENT WITH BIOGAZELLE: http://t.co/EkimyQQSZW
FlandersBio offers an up-to-date life sciences database containing all the life sciences companies with biotech activity in Flanders, and all FlandersBio members. The guide provides easy and fast access to the local life sciences community.
FlandersBio beschikt over een geüpdate databank met een overzicht van de Vlaamse bedrijven met biotechactiviteit en alle FlandersBio-leden. De databank verleent een makkelijke en vlugge toegang tot de lokale biowetenschappen-gemeenschap.
Galapagos is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action. The Company is progressing GLPG0634, as well as one of the largest pipelines in biotech, with four programs in development and over 30 discovery programs. The Galapagos Group has about 800 employees and operates facilities in five countries, with global headquarters in Mechelen, Belgium.
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size clinical stage biotechnology company specialized in the discovery and development of small molecule and antibody therapies with a novel mode-of-action. The Company is progressing four clinical, six pre-clinical, and 30 discovery programs in cystic fibrosis, inflammation, antibiotics, metabolic disease, and other indications.
Its lead program is GLPG0634, an orally-available, selective inhibitor of JAK1, for the treatment of rheumatoid arthritis and potentially other inflammatory diseases. In two four-week Phase 2 studies, GLPG0634 showed improvement in the signs and symptoms of rheumatoid arthritis and a unique safety profile. A 6 month Phase 2b study is expected to start Q2 2013 with top line data expected in Q4 2014. AbbVie and Galapagos signed a worldwide license agreement whereby AbbVie will be responsible for further development and commercialization after Phase 2b. Galapagos is also progressing two other clinical development programs with clinical readouts expected in 2013: GLPG0187, a novel integrin receptor antagonist in development for metastasis, is in a Phase 1b patient study; GLPG0974 is the first inhibitor of GPR43 to be evaluated clinically for the treatment of IBD. This program is in a second Phase 1 study and will start a Proof of Concept Phase 2 study in Q2 2013.
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and Fidelta, has over 800 employees and operates facilities in five countries, with global headquarters in Mechelen, Belgium. Further information about the company and its drug development programs can be found online at: www.glpg.com
Galapagos has discovered new drug targets (human proteins that are starting points for the development of novel drugs) using human primary cells relevant for diseases such as rheumatoid arthritis, osteoarthritis and osteoporosis. Galapagos applies these targets to find small molecules that change the activity of these proteins and thereby can influence the course of the disease.
The molecules then form the basis for the development of first-in-class medicines against these diseases. This approach is expected to yield a breakthrough in treatment by stopping the disease rather than just treating the symptoms. GLPG0634, a drug candidate discovered using this approach, has shown excellent efficacy and safety in a Proof-of-Concept Phase II trial. Furthermore, Galapagos is building a drug pipeline in orphan diseases - with cystic fibrosis as the first indication where Galapagos plans discover, develop and launch its own medicines.
Galapagos' service operations meet the pharma industry's need for drug discovery tools and expertise by providing a full range of services, from target discovery through to delivery of pre-clinical candidates. The main business areas of BioFocus, Argenta and Fidelta include biology (target discovery and screening), compound libraries, medicinal chemistry and ADME/PK services. BioFocus' and Argenta's global client base includes pharmaceutical and biotechnology companies, academic institutions and patient foundations. With operations in the UK, the Netherlands, Croatia and sales offices in Japan and Singapore, the service operations are well positioned to support this client base.
Galapagos has entered into several long term alliances with large pharma companies: Galapagos' rheumatoid arthritis program is partnered with Janssen Pharmaceutica and its immuno-inflammation program with GlaxoSmithKline. Additionally, Galapagos has established strategic alliances in fibrosis with Roche and in osteoarthritis and oncology with Servier.
Through its alliance strategy, Galapagos is eligible to receive in excess of €2.5 billion in success-dependent downstream milestone revenues plus up to double-digit royalties on commercial products. Galapagos is progressing over 30 target-based programs in R&D, the majority of which are part of the alliances.
Phone: +32 15 34 29 00
Fax: +32 15 34 29 01
Foundation date: 1/1999